Amylyx Pharmaceuticals (AMLX) Finished Goods (2022)

Amylyx Pharmaceuticals (AMLX) recorded quarterly Finished Goods of $937000.0 in Q4 2022, up 751.82% quarter-over-quarter from $110000.0 in Q3 2022.

Amylyx Pharmaceuticals (AMLX) Finished Goods (2022) Analysis & Trends

Amylyx Pharmaceuticals' Finished Goods history runs 1 years deep, the most recent figure standing at $937000.0 for Q4 2022.

  • In Q4 2022, Finished Goods changed N/A year-over-year to $937000.0; the TTM figure through Dec 2022 stood at $937000.0 (changed N/A YoY), while the FY2022 annual figure was $937000.0, changed N/A from the prior year.
  • Finished Goods was $937000.0 for Q4 2022 at Amylyx Pharmaceuticals, up from $110000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $937000.0 in Q4 2022 to a low of $110000.0 in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Amylyx Pharmaceuticals 1.51 Bn 1.51 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2022 937,000.00
Sep 30, 2022 110,000.00